Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database

Circulation. 2020 Jul 21;142(3):303-305. doi: 10.1161/CIRCULATIONAHA.120.048238. Epub 2020 May 22.

¹ Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique - Hopitaux de Paris, Clinical Investigation Center, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France (L.S.N., C.F., C.F.-B., J.-E.S.).
² Centre Medico-Chirurgical Ambroise Paré, Research & Innovation, Neuilly-sur-Seine, France (L.S.N.).
³ Pharmacoepidemiology Unit, Department of Pharmacology, Centre Hospitalo-Universitaire de Caen, Equipe d'accueil EA4650, Signalisation, Electrophysiologie et Imagerie des Lésions d'Ischémie-Reperfusion Myocardique, Normandie University, Caen, France (C.D., J.A.).
⁴ Department of Pharmacology and Toxicology, PharmacoVigilance Center, University of Nice Côte d'Azur Medical Center, Hôpital de Cimiez, France (M.-D.D.).
⁵ Groupe Hospitalier Paris Centre-Université de Paris, Cochin University Hospital, Medical Intensive Care Unit, France (J.-P.M.).
⁶ Vanderbilt University Medical Center, Departments of Medicine and Pharmacology (J.J.M., D.M.R., J.-E.S.), Nashville, TN.
⁷ Department of Biomedical Informatics (D.M.R.), Nashville, TN.

No abstract available

Keywords: azithromycin; cardiotoxicity; hydroxychloroquine; phamacovigilance.

Publication types